Irinotecan Hydrochloride Injection shortage
Not a nationwide shortage — Ingenus Pharmaceuticals has told the FDA it is discontinuing its irinotecan hydrochloride injections.
- The FDA lists this under “To be discontinued” as of Nov 21, 2026: a company stopping its own product.
- 11 other companies sell the same medicine and have not reported a problem, so your pharmacy may be able to order another company’s version.
- Status
- FDA term: “To Be Discontinued”
- Products on the record
- 2
- Category
- First posted
- Feb 24, 2026
- Last updated
- Feb 24, 2026
- Medicaid use (2026)
This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD Compiled from public FDA (openFDA) and CMS (Medicaid) data sources. Editorial policy
The Bottom Line
Ingenus is stopping irinotecan hydrochloride injection, and the change may be permanent. The same medicine is still listed by other makers that have not reported a shortage, including Camptosar (irinotecan) in 40 mg/2 mL and 100 mg/5 mL strengths.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).
Is Irinotecan Hydrochloride Being Discontinued? Status as of Nov 21, 2026
Not as a whole, as of Nov 21, 2026. Ingenus Pharmaceuticals is stopping its own version only; 11 other companies still sell the same medicine and have not reported a problem. Your pharmacy may need to order another company’s version.
The charts count only the companies that reported this shortage to the FDA; companies that haven’t reported a problem are listed after them, and the Supply-Risk rating counts them too.
Availability of the Affected Products
From the FDA shortage report: 2 products
Is Every Strength Still Made?
A medicine often comes in several strengths, and more than one company may make each. This shows whether at least one company still makes each strength on the record: a company on the shortage report that still has supply, or another company that sells it.
2 of 2 strengths
- 40 mg/2 mLStill made by a company
- 100 mg/5 mLStill made by a company
Other Companies Listing the Same Medicine, Not Reporting a Shortage
Companies that list Irinotecan Hydrochloride Injection with the FDA and have not reported a shortage (not counted in the charts above).
- Pharmacia & Upjohn Company LLC
- Hikma Pharmaceuticals USA Inc.
- Northstar Rx LLC
- Actavis Pharma, Inc.
- Eugia US LLC
- Apotex Corp.
- Hospira, Inc.
- Fresenius Kabi USA, LLC
- Qilu Pharmaceutical Co., Ltd.
- BluePoint Laboratories
- Xiromed LLC
Shortage Timeline
- Feb 24, 2026 Discontinuation notice on file 2 of 2 products affected.
- Feb 24, 2026 First reported to the FDA 2 products first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
Which Irinotecan Hydrochloride Products Are Affected, by Company
Only the companies that told the FDA about a supply problem are listed here, so other companies may still have stock (see Where else can I get irinotecan hydrochloride?).
Company: Ingenus Pharmaceuticals LLC
-
Irinotecan Hydrochloride Injection, 100 mg/5 mL
- Strength
- 100 mg/5 mL
- Availability
- Not stated
Notes: A business decision was made to discontinue manufacture of the drug.
-
Irinotecan Hydrochloride Injection, 40 mg/2 mL
- Strength
- 40 mg/2 mL
- Availability
- Not stated
Notes: A business decision was made to discontinue manufacture of the drug.
Why Is Ingenus Pharmaceuticals Discontinuing Irinotecan Hydrochloride?
A note from Dr. Brian Staiger, PharmD · Written Nov 21, 2026
I want to explain what's going on with irinotecan hydrochloride injection from Ingenus Pharmaceuticals. The FDA lists it as "to be discontinued," and the FDA didn't give a standard shortage reason code. The only explanation Ingenus shared is that it made a business decision to stop making the drug. So this isn't described as a factory problem or a surge in demand.
This report covers two Ingenus products:
- Irinotecan Hydrochloride Injection, 40 mg/2 mL (NDC 50742-401-02)
- Irinotecan Hydrochloride Injection, 100 mg/5 mL (NDC 50742-402-05)
Ingenus didn't give a date for when supply will run out, and it didn't name any strength or package size that will keep being made. This report speaks only to Ingenus and its two products. Other companies that make irinotecan aren't part of it.
What Should I Do If I Take Irinotecan Hydrochloride?
A note from Dr. Brian Staiger, PharmD · Written Nov 21, 2026
Irinotecan hydrochloride injection is currently on the FDA drug-shortage list, but the overall supply risk is rated low. The shortage report was filed by one manufacturer, Ingenus Pharmaceuticals, and it covers two strengths: 40 mg/2 mL and 100 mg/5 mL. Ingenus does not have either strength available. Both strengths are still listed by other companies that did not report a shortage, so no strength is without a source right now.
The reason given is a business decision to stop making the drug. Because this product is marked "to be discontinued," the supply problem from this maker may be permanent. Other companies still list the same medicine. These include Camptosar (Pharmacia & Upjohn) and irinotecan 20 mg/mL from makers such as Hikma, Hospira, Fresenius Kabi, and Apotex. BluePoint Laboratories lists both the 40 mg/2 mL and 100 mg/5 mL strengths. Irinotecan is usually given in a clinic or infusion center, so your care team will most likely handle sourcing.
What you can do:
- Do not skip or change any treatment on your own.
- Ask your care team or pharmacy whether they can order the same medicine from another maker. It may not be in local stock.
- Talk with your prescriber or pharmacist if your usual product can't be found. Since this maker is discontinuing it, that conversation is a good next step.
- Manufacturer contact numbers are listed on this page for reference. Pharmacies usually make these calls.
This is general information based on national FDA data reported by manufacturers. It may not match your local supply, and it is not personal medical advice.
Quick checklist for the pharmacy counter
- Ask your pharmacy to check other companies’ versions, other strengths, package sizes, and nearby stores — the options below are a starting point.
- If this is part of an ongoing or essential regimen (for example HIV, seizure, heart, transplant, diabetes or mental-health medicines), arrange continued supply before you run out rather than rationing doses.
Where Else Can I Get Irinotecan Hydrochloride?
From the current FDA NDC Directory: the same medicine from companies that have not reported a shortage.
- Some listings are repackagers, which relabel another company’s product.
- A listing is not stock: these may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Same Medicine From Other Companies (Not Reporting a Shortage)
The same active ingredient, dosage form and route, from companies that have not reported a shortage to the FDA.
| Product | Strength | Form / route | Company | NDC |
|---|---|---|---|---|
| Camptosar | 20 mg/mL | Injection, Solution · Intravenous | Pharmacia & Upjohn Company LLC | 00009-0082-02 |
| Irinotecan Hydrochloride | 20 mg/mL | Injection · Intravenous | Hikma Pharmaceuticals USA Inc. | 00143-9583-01 |
| Irinotecan Hydrochloride | 20 mg/mL | Injection · Intravenous | Northstar Rx LLC | 16714-0027-01 |
| Irinotecan Hydrochloride | 20 mg/mL | Injection, Solution · Intravenous | Actavis Pharma, Inc. | 45963-0614-51 |
| Irinotecan Hydrochloride | 20 mg/mL | Injection, Solution · Intravenous | Eugia US LLC | 55150-0352-01 |
| Irinotecan Hydrochloride | 20 mg/mL | Injection, Solution · Intravenous | Apotex Corp. | 60505-6128-00 |
| Irinotecan Hydrochloride | 20 mg/mL | Injection, Solution · Intravenous | Hospira, Inc. | 61703-0349-09 |
| Irinotecan Hydrochloride | 20 mg/mL | Injection, Solution · Intravenous | Fresenius Kabi USA, LLC | 63323-0193-52 |
| Irinotecan Hydrochloride | 20 mg/mL | Injection, Solution · Intravenous | Qilu Pharmaceutical Co., Ltd. | 67184-0511-01 |
| Irinotecan Hydrochloide | 20 mg/mL | Injection · Intravenous | BluePoint Laboratories | 68001-0480-22 |
| Irinotecan Hydrochloride | 40 mg/2 mL | Injection, Solution · Intravenous | BluePoint Laboratories | 68001-0714-34 |
| Irinotecan Hydrochloride | 100 mg/5 mL | Injection, Solution · Intravenous | BluePoint Laboratories | 68001-0715-25 |
| Irinotecan Hydrochloide | 20 mg/mL | Injection · Intravenous | Xiromed LLC | 70700-0169-22 |
Therapeutic Equivalents and Pricing 27 products
Other products the FDA rates as interchangeable with the affected strengths, with what pharmacies pay for each and whether pharmacies are still buying it. Cheapest first.
| Product | Manufacturer | Package | Pharmacy cost per unit (NADAC) | FDA rated equivalent | Availability |
|---|---|---|---|---|---|
| Camptosar 20 mg/mLNDC 00009-0112-05 | Pharmacia | 1 vial | — | AP | FDA listed |
| Irinotecan Hydrochloride 20 mg/mLNDC 00143-9583-01 | Hikma | 5 ml | — | AP | FDA listed |
| Irinotecan Hydrochloride 20 mg/mLNDC 00143-9701-01 | Hikma | 5 ml | — | AP | FDA listed |
| Irinotecan hydrochloride 20 mg/mLNDC 16714-0131-01 | Northstar | 1 vial | — | AP | FDA listed |
| Irinotecan Hydrochloride 20 mg/mLNDC 25021-0230-02 | Sagent | 1 vial | — | — | Discontinued |
| Irinotecan hydrochloride 20 mg/mLNDC 45963-0614-85 | Actavis | 1 vial | — | AP | Discontinued |
| Irinotecan Hydrochloride 100 mg/5mLNDC 50742-0402-05 | Ingenus | 1 vial | — | — | Discontinued |
| Irinotecan Hydrochloride 20 mg/mLNDC 55150-0353-01 | Eugia | 1 vial | — | AP | FDA listed |
| Irinotecan Hydrochloride 20 mg/mLNDC 60505-6128-00 | Apotex | 1 vial | — | AP | FDA listed |
| Irinotecan Hydrochloride 20 mg/mLNDC 60505-6272-01 | Apotex | 1 vial | — | AP | FDA listed |
| Irinotecan Hydrochloride 20 mg/mLNDC 61703-0349-09 | Hospira, | 1 vial | — | AP | FDA listed |
| Irinotecan Hydrochloride 20 mg/mLNDC 63323-0193-52 | Fresenius | 1 vial | — | AP | FDA listed |
| Irinotecan Hydrochloride 20 mg/mLNDC 67184-0512-01 | Qilu | 1 vial | — | AP | FDA listed |
| Irinotecan hydrochloide 20 mg/mLNDC 68001-0480-22 | BluePoint | 1 vial | — | AP | FDA listed |
| Irinotecan hydrochloride 20 mg/mLNDC 68083-0382-01 | Gland | 1 vial | — | AP | FDA listed |
| Irinotecan hydrochloride 20 mg/mLNDC 70700-0170-22 | Xiromed | 1 vial | — | AP | FDA listed |
| Irinotecan Hydrochloride 100 mg/5mLNDC 68001-0715-25 | BluePoint | 1 vial | — | AP | FDA listed |
| Camptosar 20 mg/mLNDC 00009-7529-03 | Pharmacia | 1 vial | — | AP | Discontinued |
| Irinotecan Hydrochloride 20 mg/mLNDC 00143-9702-01 | Hikma | 2 ml | — | AP | FDA listed |
| Irinotecan hydrochloride 20 mg/mLNDC 16714-0027-01 | Northstar | 1 vial | — | AP | FDA listed |
| Irinotecan Hydrochloride 40 mg/2mLNDC 50742-0401-02 | Ingenus | 1 vial | — | — | Discontinued |
| Irinotecan Hydrochloride 20 mg/mLNDC 55150-0352-01 | Eugia | 1 vial | — | AP | FDA listed |
| Irinotecan Hydrochloride 20 mg/mLNDC 55150-0355-01 | Eugia | 1 vial | — | AP | FDA listed |
| Irinotecan Hydrochloride 20 mg/mLNDC 67184-0511-01 | Qilu | 1 vial | — | AP | FDA listed |
| Irinotecan hydrochloide 20 mg/mLNDC 68083-0381-01 | Gland | 1 vial | — | AP | FDA listed |
| Irinotecan hydrochloide 20 mg/mLNDC 70700-0169-22 | Xiromed | 1 vial | — | AP | FDA listed |
| Irinotecan Hydrochloride 40 mg/2mLNDC 68001-0714-34 | BluePoint | 1 vial | — | AP | FDA listed |
These have the same ingredient, strength, form and route, and the FDA rates them as substitutes (an “AB” rating in its Orange Book). The price is what pharmacies pay on average (CMS’s NADAC survey), not what you pay. Availability comes from recent pharmacy prices, not a stock check.
Other Drugs in the Same Treatment Class
These are different medicines — not other versions of irinotecan hydrochloride — that fall in the same broad treatment class (antineoplastic - topoisomerase i inhibitors). They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Codes & Classification for pharmacists and billers
- GCN Seq No
- 062174
- GCN
- 97956
- HICL code
- 010778
- Ingredient (HICL)
- Irinotecan Hcl
- HIC1 code
- V
- Therapeutic class — broad (HIC1)
- Neoplasms
- HIC2 code
- V3
- Therapeutic class — intermediate (HIC2)
- Antineoplastic Drugs (Continued 1)
- HIC3 code
- V3E
- Therapeutic class — specific (HIC3)
- Antineoplastic - Topoisomerase I Inhibitors
- AHFS code
- 10:00.00.00
- AHFS class
- Antineoplastic Agents
- FDB label name
- IRINOTECAN HCL 100 MG/5 ML VL
- FDB brand name
- Irinotecan Hcl
- Legend status
- F — Federal legend — prescription drug or device
Where does this data come from? Identity codes come from First Databank (FDB) (HICL ingredient, HIC1–3 therapeutic-class hierarchy, GCN, AHFS class, legend status) and Medi-Span GPI, mapped from a representative affected NDC. Licensed reference data — for identification only.
Other Oncology Shortages
- Valstar Preservative Free (Valrubicin) SolutionA company is discontinuing its version · 1 product
- Leuprolide Acetate InjectionA company is discontinuing its version · 1 product
- Melphalan Hydrochloride InjectionA company is discontinuing its version · 1 product
- Nipent (Pentostatin) InjectionIn shortage · 1 product
- Fulvestrant InjectionA company is discontinuing its version · 1 product
- Treanda (Bendamustine Hydrochloride) InjectionA company is discontinuing its version · 1 product
- Lorbrena (Lorlatinib) TabletA company is discontinuing its version · 1 product
- Vizimpro (Dacomitinib) TabletA company is discontinuing its version · 3 products
Irinotecan hydrochloride Shortage FAQs
Is irinotecan hydrochloride discontinued?
Only Ingenus Pharmaceuticals’s version. Ingenus Pharmaceuticals has told the FDA it is stopping its own product (listed under “To be discontinued” as of Nov 21, 2026), while 11 other companies still sell the same medicine and have not reported a problem (Pharmacia & Upjohn, Hikma Pharmaceuticals, Northstar Rx and 8 more). It is not a nationwide shortage.
Which strengths of irinotecan hydrochloride are affected?
The FDA record covers 2 strengths: 40 mg/2 mL, 100 mg/5 mL. Every strength on the record is still made by at least one company, though stock varies by pharmacy.
Why is Ingenus Pharmaceuticals discontinuing irinotecan hydrochloride?
Ingenus Pharmaceuticals’s note on the FDA record says: “A business decision was made to discontinue manufacture of the drug.”
Which irinotecan hydrochloride products are affected?
Irinotecan Hydrochloride Injection, 100 mg/5 mL (NDC 50742-0402-05); Irinotecan Hydrochloride Injection, 40 mg/2 mL (NDC 50742-0401-02). The full per-NDC list (availability, company and status) is in the table above — each NDC links to its own page.
When will irinotecan hydrochloride be available again?
A discontinuation is usually permanent for that company’s product. The same medicine is still sold by Pharmacia & Upjohn, Hikma Pharmaceuticals, Northstar Rx and 8 more, so ask your pharmacy to order another company’s version.
Can I still get irinotecan hydrochloride somewhere?
Other companies (Pharmacia & Upjohn, Hikma Pharmaceuticals, Northstar Rx and 8 more) sell the same medicine and have not reported a problem. See “Where else can I get irinotecan hydrochloride?” above — stock still varies by pharmacy.
What should I do if I take irinotecan hydrochloride?
Don’t stop or change it on your own. Ask your pharmacist whether they can order it from another company or a different strength or package size, and ask your prescriber about a long-term plan before your supply runs out.
How to Read the Supply-Risk Rating
Each drug in shortage gets one point for each of five risk factors that apply to it (listed with its rating). It is our estimate across the country, not a check of your pharmacy’s shelves.
- Low0 to 2 risk factors Your pharmacy can often still get it, though it may need to be ordered.Irinotecan hydrochloride is rated Low: 0 of 5 risk factors.
- Medium3 risk factors Supply is tight in several ways. Finding it may take some calling around.
- High4 or 5 risk factors, or no company found making it Few companies are left making it, or some strengths have no maker at all. It may be hard to find for a while.
Back to this drug’s rating ↑ · How we rate supply risk, in full
Where This Data Comes From
- The FDA’s drug shortage database, checked every day: the companies, their products and the codes on their boxes (NDCs), the status, the reason and the dates. See the FDA’s record for this shortage ↗
- The FDA’s NDC Directory: the other companies that make the same medicine, which the supply-risk rating counts.
- CMS Medicaid prescription data: how widely it is used. It counts Medicaid prescriptions only, so it is a rough guide, not total U.S. use.
- First Databank and CMS NADAC: matching the same medicine across companies, and what pharmacies pay for the equivalents.
For reference only. Check with your pharmacist, the drug’s maker or the FDA before acting on it.